Non-invasive Biosensors Market, by Technology (Optical, Transdermal, Thermal, and Others), by Product Type (Glucose Monitors, Blood Analytes Monitors, Breathalyzers, and Others), by End User (Hospitals, Diagnostic Lab, Homecare Settings, and Others) and by Region - Global Forecast to 2026

Published In : May 2018

Code : CMI1704

Pages :173

Formats :

Excel and PDF

Industry : Medical Devices

Leading Companies

Increasing research and development and a robust pipeline of novel non-invasive biosensors is expected to drive growth of the global non-invasive biosensor market in the near future. For instance, MediWise Ltd.—a U.K.-based company—has its product GlucoWise in clinical trial. GlucoWise is a non-invasive glucose monitor device and is expected to be launched in 2018. In 2017, researchers from University of Cincinnati developed a non-invasive biosensor, which uses chemical stimulant to produce sweat and uses sweat to monitor biometrics.

Furthermore, key players in the market are participating in various conference and symposium, in order to showcase their novel non-invasive biosensors. For instance, in 2017, Integrity Applications Inc. exhibited its new GlucoTrack at American Diabetes Association’s 77th Scientific Sessions held at San Diego, U.S.

Key players operating in the non-invasive biosensors market include Nemaura Medical, Inc., MediWise Ltd., Integrity Applications Inc., OrSense, Medtronic Plc, GE Healthcare, Philips Healthcare, Akers Biosciences, Inc. and Abbott Laboratories.